Shareholder Update: Creative Medical Technology Holdings, Inc.

PHOENIX, Sept. 4, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities.

CaverStem^TM: Domestic recruitment, vetting and training of physicians on the CaverStem^TM program for the use of the patients own stem cells for the treatment of erectile dysfunction is continuing.

We wish to welcome Dr. Peter Niemczyk with The Center for Sexual and Urinary Function in Phoenix, AZ. Dr. Niemczyk holds Board Certifications in Urology and in male and female sexual dysfunction.

We are pleased to announce the addition of Amy Goldberg to the Creative Medical Technology Holdings sales team. Ms. Goldberg has decades long experience in medical device sales and will be concentrating on expanding the CaverStem^TM program to physicians in the Eastern United States.

CaverStem^TM International:

Russia: Implementation of our contract with Promo Med continues to move forward.

Switzerland: We AGAIN wish to welcome Dr. Alexander Bachmann and Alta-Uro in Bern, Switzerland. We are excited that CaverStem^TM will be performed by such highly regarded physicians.

Germany and Austria: We are continuing discussions to expand CaverStem^TM in these countries with the assistance of Dr. Bachmann and lead by Dr. Alexander Gershman, a Managing Member of CaverStem International LLC.

Italy: We have been approached by a very reputable physician interested in our CaverStem^TM program. We are optimistic that in a near future press release we will have the opportunity to welcome Dr. Antonini from Antonini Urology in Rome, Italy to CaverStem^TM. This is very encouraging as news of our expansion in Europe has resulted in physicians reaching out to the company to become involved.

CaverStem^TM Clinical Trial: To add to our press release on August 14, 2018, once the trial has reached 1 year from the last patient enrolled, which was August 28^th, the trial data collected by LA Bio Med will be submitted for peer review. Once this review is completed, our company and LA Bio Med will jointly publish the results. We understand the eagerness for trial results however as is our policy in all matters, we must follow the customary and contractual process. We will advise anticipated dates in near future releases. 

American Urological Association Regional Conference: We will be exhibiting at Booth 313 in Chicago on September 6 and 7, 2018. We encourage all physicians attending to stop by and meet the CaverStem^TM team.

Female Sexual Dysfunction: With the addition of physicians that practice in the area of both male and female sexual dysfunction we have determined that it is an appropriate time to begin development of our program related to the treatment of female sexual dysfunction. Based on publications, including The Cleveland Clinic, up to 43% of women suffer from some degree of sexual dysfunction which in many cases may be caused by the lack of blood flow. This technology which is similar to the CaverStem^TM technology for the unexpanded and minimally manipulated use of the patients own bone marrow derived stem cells is designed to aid in the increase of sensitivity by increasing blood flow. We are currently developing a brand identity for release to specific physicians experienced in the treatment of female sexual dysfunction.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.  For more information on our Caverstem^TM procedure please go to www.caverstem.com. 

Forward-Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

SOURCE Creative Medical Technology Holdings, Inc.

Related Links

http://www.creativemedicaltechnology.com